本帖最后由 老马 于 2012-1-13 21:20 编辑 / T+ q9 f) y% d
2 E+ O1 T5 Q, R* g g
爱必妥和阿瓦斯丁的比较
+ U; \! a( L% ]/ `# ?6 r$ [) O
" y' k& S) _ K* Z3 ]0 h+ `! c
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/5 J* K& s& V' J* v' s0 L
- J0 p4 P; u3 `2 d" `; A e" D2 n7 G% ~2 ]
0 ?* F4 X W2 Z Y2 R; G: I- bhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
8 b- R& [2 g* W: k; ~( }) L==================================================2 K" W) J8 y, E6 y& X( K! p
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
, I! a$ ` _& P3 a3 cPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.6 D4 J0 E/ ]) ]
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
, O) z' ~) h9 K" {6 y
|
显身卡
